Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：102頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2012', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Reflux Esophagitis (Gastroesophageal Reflux Disease).
- A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2012', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutic pipeline. This report provides information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease). 'Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Reflux Esophagitis (Gastroesophageal Reflux Disease).
- A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) 11
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics under Development by Companies 13
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Products under Development by Companies 21
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Development 24
Takeda Pharmaceutical Company Limited 24
XenoPort, Inc. 25
Novartis AG 26
Eisai Co., Ltd. 27
Wockhardt Limited 28
Shire Plc 29
Addex Pharmaceuticals 30
ARYx Therapeutics 31
Flamel Technologies S.A. 32
Ahn-Gook Pharmaceutical Co., Ltd. 33
AGI Therapeutics plc 34
Cempra Pharmaceuticals, Inc. 35
Vecta Ltd. 36
Reviva Pharmaceuticals Inc. 37
Mayne Pharma Limited 38
RaQualia Pharma Inc. 39
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
TAK-438 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ATI-7505 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
sTU-199 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ADX71943 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SPD-557 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Pariet - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
E3710 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PIVEC - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Vecam - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CR 2017 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Omeprazole suspension - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AGI-006 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Arbaclofen Placarbil - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DDP733 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
RQ-00000004 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
RQ-00000004 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
RQ-00000010 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RQ-00000010 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AG SPT201 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
OX17 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Nortriptyline - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Rozerem - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RQ-00000774 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Omeprazole - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Rabeprazole - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
TAK-390MR - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TAK-390MR - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Cimetidine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RP 3000 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Omeprazole XL - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NHP-229 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Sodium Alginate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Drug Profile Updates 86
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Discontinued Products 91
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics - Dormant Products 93
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Product Development Milestones 95
Featured News & Press Releases 95
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases 95
Sep 15, 2011: Daiichi Sankyo And AstraZeneca Launch NEXIUM 10mg And 20mg Capsules In Japan 95
Sep 09, 2011: STI Enables AstraZeneca To Allow Ongoing Choice For NEXIUM 96
Sep 02, 2011: Eisai Discontinues Development Of Pariet/Aciphex Extended-Release Capsules, 50mg 96
Aug 25, 2011: AstraZeneca Announces Launch Of NEXIUM New Savings Card Offering Instant Discounts For Patients 97
Jul 01, 2011: AstraZeneca's NEXIUM Receives First Regulatory Approval In Japan For Treatment Of Acid-related Diseases 97
May 02, 2011: FDA Approves NEXIUM I.V. For Treatment Of Gastroesophageal Reflux Disease With Erosive Esophagitis In Pediatric And Adolescent Patients 98
Mar 21, 2011: XenoPort Reports Results From Phase IIb Clinical Trial Of Arbaclofen Placarbil As Adjunctive Treatment For Patients With GERD 98
Feb 02, 2011: Eisai Receives Complete Response Letter From FDA For Rabeprazole Sodium Extended-Release Capsules, 50mg For GERD 99
Feb 02, 2011: Eisai Receives Complete Response Letter From FDA For Rabeprazole Sodium Extended-Release Capsules, 50mg For GERD 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102
List of Tables
Number of Products Under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2012 11
Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Development by Companies, H2 2012 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2012 23
Takeda Pharmaceutical Company Limited, H2 2012 24
XenoPort, Inc., H2 2012 25
Novartis AG, H2 2012 26
Eisai Co., Ltd., H2 2012 27
Wockhardt Limited, H2 2012 28
Shire Plc, H2 2012 29
Addex Pharmaceuticals, H2 2012 30
ARYx Therapeutics, H2 2012 31
Flamel Technologies S.A., H2 2012 32
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 33
AGI Therapeutics plc, H2 2012 34
Cempra Pharmaceuticals, Inc., H2 2012 35
Vecta Ltd., H2 2012 36
Reviva Pharmaceuticals Inc., H2 2012 37
Mayne Pharma Limited, H2 2012 38
RaQualia Pharma Inc., H2 2012 39
Assessment by Monotherapy Products, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 44
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Drug Profile Updates 86
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Discontinued Products 91
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Discontinued Products (Contd..1) 92
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Dormant Products 93
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Dormant Products (Contd..1) 94
List of Figures
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2012 11
Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 40
Assessment by Route of Administration, H2 2012 41
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Molecule Type, H2 2012 43
Assessment by Stage and Molecule Type, H2 2012 44
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) 11
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics under Development by Companies 13
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Products under Development by Companies 21
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Development 24
Takeda Pharmaceutical Company Limited 24
XenoPort, Inc. 25
Novartis AG 26
Eisai Co., Ltd. 27
Wockhardt Limited 28
Shire Plc 29
Addex Pharmaceuticals 30
ARYx Therapeutics 31
Flamel Technologies S.A. 32
Ahn-Gook Pharmaceutical Co., Ltd. 33
AGI Therapeutics plc 34
Cempra Pharmaceuticals, Inc. 35
Vecta Ltd. 36
Reviva Pharmaceuticals Inc. 37
Mayne Pharma Limited 38
RaQualia Pharma Inc. 39
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
TAK-438 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ATI-7505 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
sTU-199 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ADX71943 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SPD-557 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Pariet - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
E3710 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PIVEC - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Vecam - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CR 2017 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Omeprazole suspension - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
AGI-006 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Arbaclofen Placarbil - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DDP733 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
RQ-00000004 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
RQ-00000004 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
RQ-00000010 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RQ-00000010 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AG SPT201 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
OX17 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Nortriptyline - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Rozerem - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RQ-00000774 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Omeprazole - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Rabeprazole - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
TAK-390MR - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
TAK-390MR - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Cimetidine - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RP 3000 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Omeprazole XL - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
NHP-229 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Sodium Alginate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Non-Antibiotic Macrolide Program for Gastric Disorders - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Drug Profile Updates 86
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Discontinued Products 91
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics - Dormant Products 93
Reflux Esophagitis (Gastroesophageal Reflux Disease) – Product Development Milestones 95
Featured News & Press Releases 95
Sep 16, 2011: Takeda's TAK-438 Enters Into Phase III Clinical Trials In Japan For Treatment Of Acid-Related Diseases 95
Sep 15, 2011: Daiichi Sankyo And AstraZeneca Launch NEXIUM 10mg And 20mg Capsules In Japan 95
Sep 09, 2011: STI Enables AstraZeneca To Allow Ongoing Choice For NEXIUM 96
Sep 02, 2011: Eisai Discontinues Development Of Pariet/Aciphex Extended-Release Capsules, 50mg 96
Aug 25, 2011: AstraZeneca Announces Launch Of NEXIUM New Savings Card Offering Instant Discounts For Patients 97
Jul 01, 2011: AstraZeneca's NEXIUM Receives First Regulatory Approval In Japan For Treatment Of Acid-related Diseases 97
May 02, 2011: FDA Approves NEXIUM I.V. For Treatment Of Gastroesophageal Reflux Disease With Erosive Esophagitis In Pediatric And Adolescent Patients 98
Mar 21, 2011: XenoPort Reports Results From Phase IIb Clinical Trial Of Arbaclofen Placarbil As Adjunctive Treatment For Patients With GERD 98
Feb 02, 2011: Eisai Receives Complete Response Letter From FDA For Rabeprazole Sodium Extended-Release Capsules, 50mg For GERD 99
Feb 02, 2011: Eisai Receives Complete Response Letter From FDA For Rabeprazole Sodium Extended-Release Capsules, 50mg For GERD 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 102
Disclaimer 102
List of Tables
Number of Products Under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2012 11
Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Development by Companies, H2 2012 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2012 23
Takeda Pharmaceutical Company Limited, H2 2012 24
XenoPort, Inc., H2 2012 25
Novartis AG, H2 2012 26
Eisai Co., Ltd., H2 2012 27
Wockhardt Limited, H2 2012 28
Shire Plc, H2 2012 29
Addex Pharmaceuticals, H2 2012 30
ARYx Therapeutics, H2 2012 31
Flamel Technologies S.A., H2 2012 32
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 33
AGI Therapeutics plc, H2 2012 34
Cempra Pharmaceuticals, Inc., H2 2012 35
Vecta Ltd., H2 2012 36
Reviva Pharmaceuticals Inc., H2 2012 37
Mayne Pharma Limited, H2 2012 38
RaQualia Pharma Inc., H2 2012 39
Assessment by Monotherapy Products, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 44
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Drug Profile Updates 86
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Discontinued Products 91
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Discontinued Products (Contd..1) 92
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Dormant Products 93
Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics – Dormant Products (Contd..1) 94
List of Figures
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2012 11
Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 40
Assessment by Route of Administration, H2 2012 41
Assessment by Stage and Route of Administration, H2 2012 42
Assessment by Molecule Type, H2 2012 43
Assessment by Stage and Molecule Type, H2 2012 44
